Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
147.55B
Market cap147.55B
Price-Earnings ratio
19.79
Price-Earnings ratio19.79
Dividend yield
6.66%
Dividend yield6.66%
Average volume
38.86M
Average volume38.86M
High today
$26.09
High today$26.09
Low today
$25.73
Low today$25.73
Open price
$25.77
Open price$25.77
Volume
3.09M
Volume3.09M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$21.97
52 Week low$21.97

Stock Snapshot

The current Pfizer(PFE) stock price is $25.89, with a market capitalization of 147.55B. The stock trades at a price-to-earnings (P/E) ratio of 19.79 and offers a dividend yield of 6.7%.

On 2026-05-13, Pfizer(PFE) stock traded between a low of $25.73 and a high of $26.09. Shares are currently priced at $25.89, which is +0.6% above the low and -0.8% below the high.

The Pfizer(PFE)'s current trading volume is 3.09M, compared to an average daily volume of 38.86M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $21.97.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $21.97.

PFE News

Seeking Alpha 2h
Pfizer granted label expansion for hemophilia therapy Hympavzi in Europe

Pfizer (PFE) announced on Wednesday that the European Commission granted marketing authorization to expand the label of its hemophilia therapy, Hympavzi, to tre...

Pfizer granted label expansion for hemophilia therapy Hympavzi in Europe
TipRanks 3h
Pfizer says EC grants marketing approval to expand indication for Hympavzi

Pfizer (PFE) announced that the European Commission has granted marketing authorization to expand the approved indication for Hympavzi to include patients 12 ye...

Simply Wall St 13h
Pfizer PROTAC Licensing Deal With Rigel Adds Royalties To Valuation Story

Pfizer (NYSE:PFE) and Arvinas have granted global development and commercialization rights for VEPPANU, the first FDA-approved oral PROTAC for advanced or metas...

Pfizer PROTAC Licensing Deal With Rigel Adds Royalties To Valuation Story

Analyst ratings

50%

of 30 ratings
Buy
40%
Hold
50%
Sell
10%

More PFE News

TipRanks 20h
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’

After Rigel Pharmaceuticals (RIGL) announced it has entered into an exclusive global licensing agreement with Pfizer (PFE) and Arvinas (ARVN) for Veppanu for th...

Nasdaq 21h
Prediction: Pfizer Will Beat the Market Over the Next 5 Years

Key Points Pfizer's financial results have been subpar in recent years. The company's newer products are starting to come into their own. The drugmaker's pip...

Prediction: Pfizer Will Beat the Market Over the Next 5 Years
Nasdaq 1d
Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to...

Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu
Nasdaq 1d
Is Pfizer a Buy, Sell, or Hold in 2026?

Key Points Pfizer generates nearly $60 billion in annual revenue. The biggest risks facing Pfizer are upcoming patent cliffs, when drugs come off patent. Pfi...

Is Pfizer a Buy, Sell, or Hold in 2026?
Nasdaq 1d
Pfizer's Net Income Drops in Q1. Is Its Dividend Still Safe?

Key Points Pfizer's revenue rose last quarter, but profits were down by 9%. Based on its latest numbers, the company's payout ratio is now north of 91%. Acqu...

Pfizer's Net Income Drops in Q1. Is Its Dividend Still Safe?
24/7 Wall St. 2d
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? By David Moadel Published May 11, 10:53AM EDT Quick Read Moder...

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Nasdaq 2d
PFE November 20th Options Begin Trading

Investors in Pfizer Inc (Symbol: PFE) saw new options begin trading today, for the November 20th expiration. One of the key inputs that goes into the price an o...

PFE November 20th Options Begin Trading

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.